Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- Biological: allogeneic large multivalent immunogen breast cancer vaccineBiological: aldesleukin
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 14
- Registration Number
- NCT00784524
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Transplantation For Severe Osteopetrosis
Phase 2
Completed
- Conditions
- Severe Osteopetrosis
- Interventions
- Procedure: umbilical cord blood transplantationRadiation: Total Lymphoid IrradiationProcedure: marrow graft transplantation
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT00775931
- Locations
- 🇺🇸
University of MInnesota, Fairview, Minneapolis, Minnesota, United States
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Phase 1
Withdrawn
- Conditions
- Kidney CancerBreast CancerPainProstate CancerMetastatic CancerLung CancerMelanoma
- Interventions
- Dietary Supplement: genisteinRadiation: radiation therapy
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2017-12-13
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00769990
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
Phase 2
Withdrawn
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2008-09-08
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00748163
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma
Phase 2
Completed
- Conditions
- Stage IV Melanoma
- Interventions
- Biological: aldesleukinBiological: allogeneic large multivalent immunogen vaccine
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 21
- Registration Number
- NCT00726739
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase 1
Terminated
- Conditions
- Multiple Myeloma and Plasma Cell NeoplasmLeukemiaLymphomaMyelodysplastic SyndromesGraft Versus Host Disease
- Interventions
- Biological: CD4+CD25+ regulatory T cellsProcedure: allogeneic hematopoietic stem cell transplantation
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT00725062
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Prostate CancerSarcomaLung CancerMesotheliomaPancreatic CancerBreast CancerColorectal CancerHead and Neck Cancer
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT00703638
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Total Marrow Irradiation for Refractory Acute Leukemia
Phase 1
Completed
- Conditions
- Acute Lymphoblastic LeukemiaMyelodysplastic SyndromeMultiple Myeloma
- Interventions
- Radiation: total marrow irradiationProcedure: umbilical cord blood transplantationBiological: Granulocyte colony-stimulating factorBiological: HLA-matched related donor bone marrow
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT00686556
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Clinical Trial of Trametes Versicolor in Women With Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- Biological: Coriolus versicolor extract
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 11
- Registration Number
- NCT00680667
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Bastyr University, Kenmore, Washington, United States
Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism
Phase 2
Terminated
- Conditions
- Hurler's SyndromeMaroteaux-Lamy SyndromeSly SyndromeAlpha MannosidosisFucosidosisAspartylglucosaminuriaSphingolipidosesKrabbe DiseaseWolman's DiseaseNiemann-Pick Disease Type B
- Interventions
- First Posted Date
- 2008-04-29
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 18
- Registration Number
- NCT00668564
- Locations
- 🇺🇸
University of Minnesota, Fairview, Minneapolis, Minnesota, United States
© Copyright 2025. All Rights Reserved by MedPath